ONT 093

Drug Profile

ONT 093

Alternative Names: OC 144093

Latest Information Update: 26 Mar 2007

Price : $50

At a glance

  • Originator Ontogen
  • Class Antineoplastics; Imidazoles
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Mar 2003 A clinical study has been added to the pharmacokinetics section
  • 04 Feb 2003 This compound is still in active development
  • 06 Jun 2001 Phase-I clinical trials for Cancer in Canada (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top